However, TP53 mutations can result in loss of wild-type tumor-suppressing p53 function in diverse types of human cancer, including AML.10MEG3 has been implicated in the regulation of the RB pathway and thus of cell proliferation,11, 12 implying a possible role in a p53-independent pathway. This evidence concerns the gene RB1 and acute myeloid leukemia.